Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2001

Content (10 Articles)

Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines

Katherine Ory, Jérôme Lebeau, Céline Levalois, Karine Bishay, Pierre Fouchet, Isabelle Allemand, Amu Therwath, Sylvie Chevillard

Altered expression and localization of PKC eta in human breast tumors

P.A. Masso-Welch, J.S. Winston, S. Edge, K.M. Darcy, H. Asch, M.M. Vaughan, M.M. Ip

Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat

Claus Holst-Hansen, Jennifer A. Low, Ross W. Stephens, Michael D. Johnson, Peter Carmeliet, Thomas L. Frandsen, Nils Brünner, Robert B. Dickson

Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators

H. Bozcuk, G. Uslu, E. Peştereli, M. Samur, M. Ozdoğan, Ş Karaveli, F. Sargın, B. Savaş

Clinical relevance of biologic factors in male breast cancer

Marion E. Meijer-van Gelder, Maxime P. Look, Joan Bolt-de Vries, Harry A. Peters, Jan G.M. Klijn, John A. Foekens

Authors Index

Author Index, Volume 68

Subject Index

Subject index, Volume 68

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine